+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myasthenia Gravis (MG) - Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4618387
  • Drug Pipelines
  • September 2018
  • Region: Global
  • 94 Pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Alexion Pharmaceuticals
  • Argenx
  • Astellas Pharma
  • Catalyst Pharmaceuticals
  • CSL Behring
  • Grifols Therapeutics,
  • MORE

‘Myasthenia Gravis (MG) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of MG in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Myasthenia Gravis (MG) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Myasthenia Gravis (MG) - Disease Understanding and Treatment Algorithm

The Myasthenia Gravis (MG) market report gives the thorough understanding of the Myasthenia Gravis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Myasthenia Gravis in the US, Europe, and Japan.

Myasthenia Gravis Epidemiology

The Myasthenia Gravis (MG) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology {total prevalent cases, gender-specific cases, severity-specific prevalent cases [Class I, Class II (Class IIa, IIb), Class III (Class IIIa, IIIb), Class IV & Class V], auto-antibodies specific prevalent cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] and diagnosed cases} scenario of Myasthenia Gravis (MG) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According this research, total prevalent population of Myasthenia Gravis (MG) in 7 major markets was found to be 129, 267 in 2016.

Myasthenia Gravis Drug Chapters

This segment of the Myasthenia Gravis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the therapeutic market size of Myasthenia Gravis is mainly accounted by symptomatic treatments comprising acetylcholinesterase Inhibitors (Mestinon), short-term immunosuppressants (corticosteroids), long-term immunosuppressants (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid acting short-term immunomodulators (intravenous immunoglobulin, plasma exchange), and long-term immunomodulators (thymectomy). Recently, Soliris (Eculizumab) (Alexion Pharmaceuticals) got approval for MG treatment in 2017. This monoclonal antibody (MAB) is used for preventing acetylcholine receptor antibodies from affecting muscle cells and is helpful for patients resistant to the other available therapies, it has significantly impacted the market size of Myasthenia Gravis after its launch. Detailed chapter for upcoming therapies like Rozanolixizumab (UCB Pharma); CFZ533 (Novartis); Efgartigimod (Argenx); RA101495 (Ra Pharmaceuticals); Firdapse (Catalyst Pharmaceuticals); Hizentra (CSL Behring); and IGIV-C (Grifols Therapeutics) have also been covered in the report.

Myasthenia Gravis Market Outlook

The Myasthenia Gravis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According this research, the market of Myasthenia Gravis in 7MM was found to be USD 2998.1 million in 2016.

Myasthenia Gravis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Myasthenia Gravis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Myasthenia Gravis Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Myasthenia Gravis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This report will help to develop Business Strategies by understanding the trends shaping and driving Myasthenia Gravis market
  • Organize sales and marketing efforts by identifying the best opportunities for Myasthenia Gravis market
  • To understand the future market competition in the Myasthenia Gravis market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alexion Pharmaceuticals
  • Argenx
  • Astellas Pharma
  • Catalyst Pharmaceuticals
  • CSL Behring
  • Grifols Therapeutics,
  • MORE
1. Key Insights

2. Myasthenia Gravis Market Overview at a Glance

3. Market Share (%) Distribution of MG in 2017

4. Market Share (%) Distribution of MG in 2027

5. Disease Overview: Myasthenia Gravis
5.1. Introduction
5.2. Types of Myasthenia Gravis
5.3. MGFA Classification of Myasthenia Gravis
5.4. Etiology
5.5. Genetic Basis of Myasthenia Gravis
5.6. Risk Factors
5.7. Signs and Symptoms
5.8. Pathophysiology of Myasthenia Gravis
5.9. Comorbid conditions in MG
5.10. Diagnosis

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Population and Forecast Parameters
6.3. 7MM Total Prevalent Patient Population of Myasthenia Gravis
6.4. Country Wise-Epidemiology of Myasthenia Gravis
6.4.1. United States
6.4.2. Assumptions and Rationale
6.4.3. Prevalent cases of Myasthenia Gravis in the United States
6.4.4. Gender-specific Prevalent Cases of Myasthenia Gravis in the US
6.4.5. Diagnosed cases of Myasthenia Gravis in the US
6.4.6. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in the US
6.4.7. Autoantibodies- specific Diagnosed Prevalent cases of Myasthenia Gravis in the US
6.4.8. Germany
6.4.9. Assumptions and Rationale
6.4.10. Prevalent cases of Myasthenia Gravis in Germany
6.4.11. Gender-specific Prevalent Cases of Myasthenia Gravis in Germany
6.4.12. Diagnosed cases of Myasthenia Gravis in Germany
6.4.13. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Germany
6.4.14. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Germany
6.4.15. France
6.4.16. Assumptions and Rationale
6.4.17. Prevalent cases of Myasthenia Gravis in France
6.4.18. Gender-specific Prevalent Cases of Myasthenia Gravis in France
6.4.19. Diagnosed cases of Myasthenia Gravis in France
6.4.20. Severity-specific Prevalent Cases of Myasthenia Gravis in France
6.4.21. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in France
6.4.22. Italy
6.4.23. Assumptions and Rationale
6.4.24. Prevalent cases of Myasthenia Gravis in Italy
6.4.25. Gender-specific Prevalent Cases of Myasthenia Gravis in Italy
6.4.26. Diagnosed cases of Myasthenia Gravis in Italy
6.4.27. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Italy
6.4.28. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Italy
6.4.29. Spain
6.4.30. Assumptions and Rationale
6.4.31. Prevalent cases of Myasthenia Gravis in Spain
6.4.32. Gender-specific Prevalent Cases of Myasthenia Gravis in Spain
6.4.33. Diagnosed cases of Myasthenia Gravis in Spain
6.4.34. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Spain
6.4.35. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Spain
6.4.36. United Kingdom
6.4.37. Assumptions and Rationale
6.4.38. Prevalent cases of Myasthenia Gravis in the United Kingdom
6.4.39. Gender-specific Prevalent Cases of Myasthenia Gravis in the United Kingdom
6.4.40. Diagnosed cases of Myasthenia Gravis in the United Kingdom
6.4.41. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in the United Kingdom
6.4.42. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in the UK
6.4.43. Japan
6.4.44. Assumptions and Rationale
6.4.45. Prevalent cases of Myasthenia Gravis in Japan
6.4.46. Gender-specific Prevalent Cases of Myasthenia Gravis in Japan
6.4.47. Diagnosed cases of Myasthenia Gravis in Japan
6.4.48. Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis in Japan
6.4.49. Autoantibodies specific Diagnosed Prevalent cases of Myasthenia Gravis in Japan

7. Current Treatment Practices
7.1. International Consensus Guidance for Management of Myasthenia Gravis
7.2. Japanese Clinical Guidelines for Myasthenia Gravis

8. Unmet Needs

9. Marketed drugs
9.1. Key cross competition- Marketed drugs
9.2. Soliris: Alexion Pharmaceuticals
9.2.1. Drug Description
9.2.2. Regulatory Milestones
9.2.3. Advantages & Disadvantages
9.2.4. Clinical Development
9.2.5. Safety and Efficacy
9.2.6. Product Profile
9.3. Mestinon: Valeant Pharmaceuticals
9.3.1. Drug Description
9.3.2. Regulatory Milestones
9.3.3. Advantages & Disadvantages
9.3.4. Safety and Efficacy
9.3.5. Product Profile
9.4. Prograf: Astellas Pharma
9.4.1. Drug Description
9.4.2. Regulatory Milestones
9.4.3. Clinical Development
9.4.4. Safety and Efficacy
9.4.5. Product Profile
9.5. Venoglobulin IH: Mitsubishi Tanabe Pharma
9.5.1. Drug Description
9.5.2. Regulatory Milestones
9.5.3. Advantages & Disadvantages
9.5.4. Clinical Development
9.5.5. Product Profile

10. Emerging Therapies
10.1. Key cross competition- Emerging Therapies
10.2. Phase-III Drugs
10.3. Firdapse: Catalyst Pharmaceuticals
10.3.1. Product Description
10.3.2. Other Development Activities
10.3.3. Clinical Development
10.3.4. Safety and Efficacy
10.3.5. Product Profile
10.4. Hizentra: CSL Behring
10.4.1. Product Description
10.4.2. Clinical Development
10.4.3. Safety and Efficacy
10.4.4. Product Profile
10.5. IGIV-C: Grifols Therapeutics
10.5.1. Product Description
10.5.2. Other Development Activities
10.5.3. Clinical Development
10.5.4. Product Profile
10.6. Phase-II Drugs
10.7. Rozanolixizumab: UCB Pharma
10.7.1. Product Description
10.7.2. Clinical Development
10.7.3. Safety and Efficacy
10.7.4. Product Profile
10.8. CFZ533: Novartis
10.8.1. Product Description
10.8.2. Clinical Development
10.8.3. Product Profile
10.9. Efgartigimod : Argenx
10.9.1. Product Description
10.9.2. Other Development Activities
10.9.3. Clinical Development
10.9.4. Safety and Efficacy
10.9.5. Product Profile
10.10. RA101495: Ra Pharmaceuticals
10.10.1. Product Description
10.10.2. Other Development Activities
10.10.3. Clinical Development
10.10.4. Safety and Efficacy
10.10.5. Product Profile

11. Myasthenia Gravis: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Size of Myasthenia Gravis in 7MM

12. Market Outlook by Country
12.1. The United States: Market Outlook
12.1.1. United States Market Size
12.1.2. Total Market size of Myasthenia Gravis
12.1.3. Market Size of Myasthenia Gravis by Current Therapies
12.1.4. Market Size of Myasthenia Gravis by Emerging Therapies
12.2. EU-5 Countries: Market Outlook
12.3. Germany
12.3.1. Total Market size of Myasthenia Gravis
12.3.2. Market Size of Myasthenia Gravis by Current Therapies
12.3.3. Market Size of Myasthenia Gravis by Emerging Therapies
12.4. France
12.4.1. Total Market size of Myasthenia Gravis
12.4.2. Market Size of Myasthenia Gravis by Current Therapies
12.4.3. Market Size of Myasthenia Gravis by Emerging Therapies
12.5. Italy
12.5.1. Total Market size of Myasthenia Gravis
12.5.2. Market Size of Myasthenia Gravis by Current Therapies
12.5.3. Market Size of Myasthenia Gravis by Emerging Therapies
12.6. Spain
12.6.1. Total Market size of Myasthenia Gravis
12.6.2. Market Size of Myasthenia Gravis by Current Therapies
12.6.3. Market Size of Myasthenia Gravis by Emerging Therapies
12.7. United Kingdom
12.7.1. Total Market size of Myasthenia Gravis
12.7.2. Market Size of Myasthenia Gravis by Current Therapies
12.7.3. Market Size of Myasthenia Gravis by Emerging Therapies
12.8. Japan: Market Outlook
12.8.1. Total Market size of Myasthenia Gravis
12.8.2. Market Size of Myasthenia Gravis by Current Therapies
12.8.3. Market Size of Myasthenia Gravis by Emerging Therapies

13. Market Drivers

14. Market Barriers

15. Appendix

16. Report Methodology

17. The Publisher Capabilities

18. Disclaimer

19. About the publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alexion Pharmaceuticals
  • Valent Pharmaceuticals
  • Astellas Pharma
  • Mitsubishi Tanabe Pharma
  • Catalyst Pharmaceuticals
  • CSL Behring
  • Grifols Therapeutics,
  • UCB Pharma
  • Novartis
  • Argenx
  • Ra Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll